Article Text
Letter
Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy
Statistics from Altmetric.com
Footnotes
-
R Idilman was supported by the Turkish Academy of Sciences, in the framework of the Young Scientist Award Program (EA-TUBA-GEBIP/2001-1-1).
-
Conflict of interest: None declared.